Royal Bank of Canada’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-8
| Closed | – | – | 7721 |
|
|
2024
Q1 | $0 | Sell |
8
-5
| -38% | -$24 | ﹤0.01% | 7776 |
|
|
2023
Q4 | $0 | Hold |
13
| – | – | ﹤0.01% | 7744 |
|
|
2023
Q3 | $0 | Sell |
13
-1
| -7% | -$5 | ﹤0.01% | 7775 |
|
|
2023
Q2 | $0 | Buy |
+14
| New | +$256 | ﹤0.01% | 7794 |
|
|
2022
Q4 | – | Sell |
-1
| Closed | – | – | 7889 |
|
|
2022
Q3 | $0 | Buy |
+1
| New | +$38 | ﹤0.01% | 8013 |
|
|
2022
Q2 | – | Sell |
-200
| Closed | -$11K | – | 7848 |
|
|
2022
Q1 | $11K | Buy |
+200
| New | +$10.1K | ﹤0.01% | 6922 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7121 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7205 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7219 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7019 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6899 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6981 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7053 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6826 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6876 |
|
Other funds holding TCON
Royal Bank of Canada's TCON Position: Q2 2024 in Review
Royal Bank of Canada sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 8 shares.
Royal Bank of Canada first reported a position in TCON in Q1 2022 and held it in 6 quarters. The position peaked at $11K in Q1 2022. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Royal Bank of Canada reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 8 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024.
- Royal Bank of Canada first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
- Royal Bank of Canada's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q1 2022.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.